Also today, Array announced the planned start of its first company-led Phase 3 trial with MEK162 in low-grade serous ovarian cancer.

Array Biopharma Inc (NASDAQ:ARRY) shares fell 9.66% to $5.24. The company, on May 6, announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer (LGSOC) during the summer of 2013.

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical ...

Apr 23, 2013 (ACCESSWIRE-TNW via COMTEX) -- New York (April 23rd, 2013) - Array BioPharma Inc. (NASDAQ:ARRY) traded in the range of $5.97 and $6.56 during its latest trading session, which is also its 52 weeks high price point.

BOULDER, Colo., May 8, 2013 -- /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas and the UBS ...

Array Biopharma Inc (NASDAQ:ARRY) shares fell 9.66% to $5.24. The company, on May 6, announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer (LGSOC) during the summer of 2013.

AbbVie Inc. (NYSE:ABBV)soared 4.27% and closed at $44.20 on a traded volume of 8.53 million shares.The stock was up after Morgan Stanley upgraded the rating of AbbVie to overweight from equal weight and liftedthe price target to $49 per share from $36.

RF Micro Devices, Inc. (NASDAQ:RFMD) stock increased 4.74% to $5.30. The company will host a conference call to review fiscal 2013 fourth quarter financial results on Tuesday, April 23, 2013, at 5:00 p.m.

Annaly Capital Management, Inc.(NYSE:NLY)moved down 0.70% and closed at $15.64 on a traded volume of 9.45 million shares.Annaly Capital Management, Inc. and CreXus Investment Corp. announced the final results of the tender offer which ...

Array Biopharma Inc. (NASDAQ:ARRY) augmented 6.88% to $6.37 on a traded volume of 1.29 million shares. The 52-week range for the stock is $3.0 and $6.17.